Less than a year after the World Health Organization (WHO) declared COVID-19 a global pandemic, the authorization of several novel COVID-19 vaccines has created hope for a healthier future. Recent studies have demonstrated that both humoral and cellular immunity play a role in protection from COVID-19. Additionally, the development of novel COVID-19 vaccines requires a look at the immune response in order to determine the effectiveness of the vaccine at preventing infection.
There is a need for continuous monitoring of therapeutic levels of TNF-α inhibitors to promote individualized treatment while affirming that patients receive the most accurate and cost-effective regimen available. With the MabTrack ELISA, clinicians can make effective adjustments based on semi-quantitative results and can facilitate simplified decision-making with their patients for improved long-term response.
SARS-CoV-2, commonly known as the coronavirus disease 2019 (COVID-19) poses an unprecedented public health crisis. While scientists and clinicians worldwide are still working to understand the virus, recent studies show possible onset of autoimmune diseases following COVID-19 infection.
The recent study conducted by De Meyer et al. demonstrated that EUROIMMUN ELISA and SIMOA (single molecule array) platform detected cerebral amyloidosis with equivalent accuracy through measuring the plasma Aβ42/Aβ40 ratio.